BrainsWay Ltd. (BWAY)
BWAYNASDAQ-GMMedical/Dental Instruments
$10.59
-1.06 (-9.06%) today
Regular session, Nov 10, 12:09 PM ET
- Market cap
- $424.77m
- P/E
- 24.1
- EPS, last 4 quarters
- $0.4400
- Dividend yield
- –
- Day range
- $10.21 to $11.11
- 52-week range
- $7.14 to $17.40
- Average volume
- 96.6k
- Previous close
- $11.64
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $19.50, +84.2% from here
Earnings
next estimate $0.1200Next report
Sep 2025
-20.0%
Dec 2025
+133.3%
Mar 2026
+140.0%
Jun 2026
+40.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2016 | Dec 2017 | Dec 2018 |
|---|---|---|---|
| Revenue | $11.52m | $3.60m | $4.77m |
| Gross profit | $9.10m | $2.69m | $3.67m |
| Operating income | -$2.07m | -$2.08m | -$1.75m |
| Net income | -$2.40m | -$2.79m | -$2.15m |
News
8 latest- BrainsWay Ltd. Amends Notice of Annual General Meeting Scheduled for November 25, 2026Fintel · Oct 26, 2026
- BrainsWay Expands U.S. Insurance Coverage for Deep TMS Treatment of OCD to Over 118 Million LivesFintel · Oct 26, 2026
- BrainsWay - Depositary Receipt Price Target Increased by 218.89% to $0.20Fintel · Oct 23, 2026
- BrainsWay Ltd. Announces Annual General Meeting of Shareholders to Be Held on November 25, 2026Fintel · Oct 21, 2026
- Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials RTTNews · Sep 11, 2026
- Are Options Traders Betting on a Big Move in Brainsway Stock?Zacks · Sep 9, 2026
- BrainsWay Reports Positive Pilot Study Results For Deep TMS In Depression & Early Alzheimer's RTTNews · Sep 8, 2026
- Lifeward Names Josh Hexter Interim CEO, Rami Aviram As CFO RTTNews · Aug 31, 2026
The company
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GM
- Region
- Middle East
- Website
- brainsway.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.